Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ABBV-744 + navitoclax
- Development stage
- Unknown
- Lead developer
- AbbVie
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
**ABBV-744 + navitoclax** is a combination therapy being evaluated primarily for the treatment of myelofibrosis. ABBV-744 is a highly selective inhibitor of the second bromodomain (BD2) of BET family proteins, which functions as an epigenetic modulator by blocking the activity of proteins such as BRD2, BRD3, BRD4, and BRDT, implicated in the transcriptional regulation of oncogenic and proinflammatory genes. Navitoclax (ABT-263) is a small molecule inhibitor targeting anti-apoptotic B-cell lymphoma 2 (BCL-2) family proteins, specifically BCL-2, BCL-XL, and BCL-w, facilitating apoptotic cell death in malignant cells. This combination is intended to synergistically suppress abnormal cell proliferation and enhance apoptosis in myelofibrosis and possibly other hematological malignancies that are resistant to Janus kinase inhibitor therapy. Trials are ongoing to characterize its safety, pharmacokinetics, and efficacy in various patient populations[1][3][4].
- Other names
- ABBV-744ABBV744ABBV 744navitoclaxABT-263ABT263ABT 263
02
Targets
BCL2L1 (B-cell lymphoma-extra large protein)BRD2 BD2 (Bromodomain-containing protein 2, bromodomain 2)MCL1 (Myeloid cell leukemia sequence 1)Bromodomain-containing protein 4, Bromodomain 2BRDT BD2 (Bromodomain testis-specific protein (BRDT), bromodomain 2)BRD3 BD2 (Bromodomain-containing protein 3 (BRD3) bromodomain 2 (BD2))BCL2L2 (BCL-2-like protein 2)BRD4 (Bromodomain-containing protein 4)
Beyond the preview
Go deeper on ABBV-744 + navitoclax.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ABBV-744 + navitoclax.